ResearchPUBMEDApr 1
Researchers in Italy tested a new way to diagnose rare genetic diseases in children using whole genome sequencing—a test that reads all of a person's genetic code. Between 2018 and 2022, they studied 64 children with complex neurological problems that doctors couldn't figure out. This study shows whether this genetic test could help find answers faster for kids with mysterious rare diseases.
WHY IT MATTERSIf your child has unexplained neurological symptoms and multiple doctors haven't found a diagnosis, this research demonstrates that whole genome sequencing through healthcare systems may finally provide answers—potentially ending years of diagnostic uncertainty.
ResearchPUBMEDMar 26
Researchers studied how medicines for rare diseases are developed by non-industry groups like universities and charities, compared to pharmaceutical companies. Between 2000 and 2022, only about 7% of rare disease medicine projects came from these non-industry organizations. While these groups got help from regulators at similar rates as companies, very few of their medicines actually made it to patients—only six succeeded, and all had to partner with pharmaceutical companies to finish the job.
WHY IT MATTERSThis research shows that academic and charity-led rare disease drug projects face significant barriers to reaching patients, suggesting that funding and regulatory support for non-industry developers could unlock more treatment options for rare diseases that pharmaceutical companies might overlook.
ResearchPUBMEDMar 26
Scientists studied a large group of patients in Europe with rare diseases caused by problems in mitochondrial aminoacyl-tRNA synthetases—proteins that help mitochondria (the energy centers of cells) make other proteins. They found 38 patients with 63 different genetic changes and created a method to match patients' symptoms with similar cases in medical literature, which helps doctors figure out what disease a patient actually has.
WHY IT MATTERSIf you or your child has unexplained seizures, developmental delays, or neurological symptoms, this research provides doctors with a new tool to identify whether mitochondrial aminoacyl-tRNA synthetase variants are the cause—potentially leading to a diagnosis after years of testing.